Efficacy and Safety of MCS-5 in Treating Male Oligoasthenospermia

NCT01016340 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2023-12-21

No results posted yet for this study

Summary

This is a phase II randomized, double-blind, placebo-controlled study where eligible subfertile male subjects (age 20 years).

Conditions

  • Male Oligoasthenospermia

Interventions

DRUG

MCS

MCS-5 Softgel 5 mg

Sponsors & Collaborators

  • Health Ever Bio-Tech Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2012-12-31
Completion
2013-06-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01016340 on ClinicalTrials.gov